OBJECTIVE: This trial was performed to evaluate the efficacy of an adjunctive cognitive-behavioral treatment compared with rheumatological treatment alone in unselected rheumatoid arthritis outpatients. DESIGN: A prospective randomized control design was used. Change in medication during treatment was controlled by matching therapy- and control-group subjects according to this change in medication, sex, age, duration of disease, and functional class. SETTING: A rheumatological outpatient clinic, University of Goettingen, Germany. PATIENTS: Fifty-five consecutive outpatients with a diagnosis of rheumatoid arthritis (age 52.7 years, 74.5% female, duration of disease 9.4 years) finished the study. INTERVENTIONS: Subjects received routine care by the rheumatologists and routine medical treatment. Cognitive-behavioral treatmentsubjects (n = 19) receivedadjunctive standardized cognitive-behavioral group treatment with 12 weekly sessions. OUTCOME MEASURES: Outcome measures included disease activity variables, pain variables (pain intensity, affective pain), psychological symptoms, and coping. RESULTS: Subjects mostly demonstrated an increasing disease activity during treatment; change in medication during treatment was necessary in some patients. In the cognitive-behavioral treatment group the course of rheumatoid arthritis seemed less progressive than in the control group. The core effects of cognitive-behavioral treatment pertain more to improved coping, emotional stabilization, and reduced impairment than to reduced pain intensity. Passive, emotion-focused coping, helplessness, depression, anxiety, affective pain, and fluctuation of pain are reduced, "Acceptance of Illness" is improved. CONCLUSIONS:Cognitive-behavioral therapy has proven an effective adjunct to standard treatment of rheumatoid arthritis outpatients. These effects were shown in an unselected sample with increasing disease activity and with comparable changes in medication during treatment. We recommend cognitive-behavioral treatment as an desirable adjunct to standard medical treatment of rheumatoid arthritis.
RCT Entities:
OBJECTIVE: This trial was performed to evaluate the efficacy of an adjunctive cognitive-behavioral treatment compared with rheumatological treatment alone in unselected rheumatoid arthritis outpatients. DESIGN: A prospective randomized control design was used. Change in medication during treatment was controlled by matching therapy- and control-group subjects according to this change in medication, sex, age, duration of disease, and functional class. SETTING: A rheumatological outpatient clinic, University of Goettingen, Germany. PATIENTS: Fifty-five consecutive outpatients with a diagnosis of rheumatoid arthritis (age 52.7 years, 74.5% female, duration of disease 9.4 years) finished the study. INTERVENTIONS: Subjects received routine care by the rheumatologists and routine medical treatment. Cognitive-behavioral treatment subjects (n = 19) received adjunctive standardized cognitive-behavioral group treatment with 12 weekly sessions. OUTCOME MEASURES: Outcome measures included disease activity variables, pain variables (pain intensity, affective pain), psychological symptoms, and coping. RESULTS: Subjects mostly demonstrated an increasing disease activity during treatment; change in medication during treatment was necessary in some patients. In the cognitive-behavioral treatment group the course of rheumatoid arthritis seemed less progressive than in the control group. The core effects of cognitive-behavioral treatment pertain more to improved coping, emotional stabilization, and reduced impairment than to reduced pain intensity. Passive, emotion-focused coping, helplessness, depression, anxiety, affective pain, and fluctuation of pain are reduced, "Acceptance of Illness" is improved. CONCLUSIONS: Cognitive-behavioral therapy has proven an effective adjunct to standard treatment of rheumatoid arthritis outpatients. These effects were shown in an unselected sample with increasing disease activity and with comparable changes in medication during treatment. We recommend cognitive-behavioral treatment as an desirable adjunct to standard medical treatment of rheumatoid arthritis.
Authors: Arthur J Barsky; David K Ahern; E John Orav; Yvonne Nestoriuc; Matthew H Liang; Ilana T Berman; Joshua R Kingsbury; Jennifer T Sy; Kathryn G Wilk Journal: Semin Arthritis Rheum Date: 2010-12 Impact factor: 5.532
Authors: Benjamin H Balderson; Susan M McCurry; Michael V Vitiello; Susan M Shortreed; Bruce D Rybarczyk; Francis J Keefe; Michael Von Korff Journal: Behav Sleep Med Date: 2015-10-20 Impact factor: 2.964
Authors: Gianluca Castelnuovo; Emanuele M Giusti; Gian Mauro Manzoni; Donatella Saviola; Arianna Gatti; Samantha Gabrielli; Marco Lacerenza; Giada Pietrabissa; Roberto Cattivelli; Chiara A M Spatola; Stefania Corti; Margherita Novelli; Valentina Villa; Andrea Cottini; Carlo Lai; Francesco Pagnini; Lorys Castelli; Mario Tavola; Riccardo Torta; Marco Arreghini; Loredana Zanini; Amelia Brunani; Paolo Capodaglio; Guido E D'Aniello; Federica Scarpina; Andrea Brioschi; Lorenzo Priano; Alessandro Mauro; Giuseppe Riva; Claudia Repetto; Camillo Regalia; Enrico Molinari; Paolo Notaro; Stefano Paolucci; Giorgio Sandrini; Susan G Simpson; Brenda Wiederhold; Stefano Tamburin Journal: Front Psychol Date: 2016-02-19
Authors: Mark A Lumley; Francis J Keefe; Angelia Mosley-Williams; John R Rice; Daphne McKee; Sandra J Waters; R Ty Partridge; Jennifer N Carty; Ainoa M Coltri; Anita Kalaj; Jay L Cohen; Lynn C Neely; Jennifer K Pahssen; Mark A Connelly; Yelena B Bouaziz; Paul A Riordan Journal: J Consult Clin Psychol Date: 2014-05-26
Authors: Sabine J M de Brouwer; Floris W Kraaimaat; Fred C G J Sweep; Rogier T Donders; Agnes Eijsbouts; Saskia van Koulil; Piet L C M van Riel; Andrea W M Evers Journal: PLoS One Date: 2011-12-06 Impact factor: 3.240
Authors: Kelly Warmington; Carol Flewelling; Carol A Kennedy; Rachel Shupak; Angelo Papachristos; Caroline Jones; Denise Linton; Dorcas E Beaton; Sydney Lineker Journal: Open Access Rheumatol Date: 2017-02-24
Authors: Sabine J M de Brouwer; Henriët van Middendorp; Floris W Kraaimaat; Timothy R D J Radstake; Irma Joosten; A Rogier T Donders; Agnes Eijsbouts; Saskia Spillekom-van Koulil; Piet L C M van Riel; Andrea W M Evers Journal: Arthritis Res Ther Date: 2013 Impact factor: 5.156